Navigation Links
Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
Date:11/19/2008

KVISTGARD, Denmark, November 19 /PRNewswire-FirstCall/ -- Bavarian Nordic has invoiced the U.S. authorities for another milestone payment of USD 25 million as allowed under the RFP-3 contract to manufacture and deliver 20 million doses of the company's IMVAMUNE(R) smallpox vaccine. This milestone payment was triggered by the recent submission of a clinical safety report from a large Phase II study with IMVAMUNE(R) in HIV infected subjects, which is part of the regulatory package that will be used to potentially support the use of IMVAMUNE(R) in a declared emergency. With this, Bavarian Nordic is an important step closer to fulfilling the conditions for initiating delivery of IMVAMUNE(R) in 2009.

The income will be recognised as revenue in the financial statements for 2008.

With this payment, Bavarian Nordic has so far invoiced a total of USD 125 million in advance- and milestone payments under the RFP-3 contract, of which USD 50 million has not yet been recognised in the income statement.

This announcement does not change Bavarian Nordic's previously announced financial guidance for 2008.

Anders Hedegaard, President & CEO of Bavarian Nordic, said: "Since the award of the RFP-3 we have successfully met all agreed objectives in the contract with the U.S. Department of Health and Human Services and we find this very satisfactory. The submission of these clinical data concludes the data package that may support the use of IMVAMUNE(R) in a declared emergency and marks an important event for the company this year. This submission is part of the company's plan to support the delivery of IMVAMUNE(R) which is planned to start during 2009".

About Bavarian Nordic

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's business strategy is focused in three areas: biodefence, cancer and infectious diseases. Bavarian Nordic's proprietary and patented technology MVA-BN(R) is one of the world's safest, multivalent vaccine vectors. Bavarian Nordic has ongoing contracts with the U.S. government for the late-stage development and procurement of the company's third-generation smallpox vaccine, IMVAMUNE(R).

Bavarian Nordic is listed on the NASDAQ OMX Copenhagen under the symbol BAVA.

For more information please visit http://www.bavarian-nordic.com

Forward-looking statements

This announcement includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.


'/>"/>
SOURCE Bavarian Nordic A/S
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
2. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
3. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
4. Cellectricon Receives Milestone Order for Cellaxess(R)HT, the Worlds First High Throughput RNAi Screening System
5. China Medical Technologies Receives SFDA Approval for Breast Cancer HER-2 FISH Probe
6. West Michigans Newest Medical Device Company Receives Support from the West Michigan Science & Technology Initiative and EDF Ventures
7. ProtoKinetix Receives Independent Confirmation of AAGP Anti-Inflammatory Action
8. Valor Medical Closes $1.4 Million Convertible Debt and Receives ISO 13485 Certification
9. Aposense Receives Frost & Sullivan Technology Innovation of the Year Award
10. Solos Endoscopy, Inc. Receives Purchase Order from Connecticut Hospital
11. Caraco Pharmaceutical Laboratories, Ltd. Receives FDA Warning Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... Columbus, OH (PRWEB) , ... August 16, 2017 ... ... of a beneficial microbe delivery system, announced it has secured $2M in funding ... Funds, Queen City Angels, Carmen Innovations, and SVG Thrive Fund. With this investment, ...
(Date:8/15/2017)... ... ... Kapstone Medical is proud to announce that it has reached a ... develop and safeguard their latest innovations. The company has grown from a boutique ... in the United States and around the world. , Company Founder and President, ...
(Date:8/15/2017)... ... ... The Conference Forum and The Trout Group will ... upcoming panels and events. The partnership culminates with the 4th Annual IO360° summit ... City. , “With our experience in producing the Immuno-Oncology 360° NYC event and The ...
(Date:8/14/2017)... York, NY (PRWEB) , ... August 14, 2017 , ... ... in Clinical Trials event, which will take place on September 6, 2017 at ... Daniel Karlin, MD , Head of Experimental Medicine, Informatics, and Regulatory Strategy, Pfizer Innovative ...
Breaking Biology Technology:
(Date:5/23/2017)... 2017  Hunova, the first robotic gym for the rehabilitation and functional ... in Genoa, Italy . The first 30 robots will ... USA . The technology was developed and patented at ... IIT spin-off Movendo Technology thanks to a 10 million euro investment from ... click: ...
(Date:5/16/2017)...   Bridge Patient Portal , an enterprise ... EMR Systems , an electronic medical record solutions ... established a partnership to build an interface between ... Centricity™ products, including Centricity Practice Solution (CPS), Centricity ... new integrations will allow healthcare delivery networks using ...
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
Breaking Biology News(10 mins):